[Some immune functions of patients with carcinoma]

To evaluate efficiency of LAK cells from patients with cancer a number of immune functions of patients with advanced carcinoma was investigated. The results showed that: from patients with cancer, lymphocyte transformation (32.83 +/- 52.59), responses of lymphocytes to IL-2 (5.94 +/- 9.31), and to IL-2/PHA (32.25 +/- 43.05), and NK activity (11.18 +/- 6.98), LAK activity (17.86 +/- 9.57) were significantly suppressed (In the healthy donors, the data were 75.70 +/- 52.65, 24.59 +/- 28.25, 125.47 +/- 74.11 respectively, P < 0.001); sIL-2R and TNF concentrations (241.9 +/- 172.5 pmol/L and 1.86 +/- 1.52 ng/ml respectively) in serum from patients with cancer were significantly higher than that of healthy control (134.2 +/- 73.5 pmol/L and 0.63 +/- 0.20 ng/ml respectively, P < 0.05-0.001). Since patients with cancer had suppressed responses of lymphocytes to IL-2, low NK and LAK cell activity, LAK cells from patients with cancer might be less effective than those from healthy donor in the treatment of cancer.